



Designation: **F2313 – 10 F2313 – 18**

## Standard Specification for Poly(glycolide) and Poly(glycolide-co-lactide) Resins for Surgical Implants with Mole Fractions Greater Than or Equal to 70 % Glycolide<sup>1</sup>

This standard is issued under the fixed designation F2313; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon ( $\epsilon$ ) indicates an editorial change since the last revision or reapproval.

### 1. Scope

1.1 This specification covers both virgin poly(glycolide) homopolymer and poly(glycolide-co-lactide) copolymer resins intended for use in surgical implants. The ~~poly(glycolide-co-lactide)~~ poly(glycolide-co-lactide) copolymers covered by this specification possess nominal mole fractions greater than or equal to ~~70 % glycolide (65.3 %)~~ 70 % glycolide (65.3 % in mass fraction). This specification is also applicable to lactide-co-glycolide copolymers that possess glycolide segments sufficient in size to deliver potential for ~~glycolide-based~~ glycolide-based crystallization, thereby requiring fluorinated solvents for complete dissolution under room temperature conditions.

1.2 Since poly(glycolide) is commonly abbreviated as PGA for poly(glycolic acid) and poly(lactide) is commonly abbreviated as PLA for poly(lactic acid), these polymers are commonly referred to as PGA, PLA, and PLA:PGA resins for the hydrolytic byproducts to which they respectively degrade. PLA is a term that carries no stereoisomeric specificity and therefore encompasses both the amorphous atactic/syndiotactic DL-lactide-based polymers and copolymers as well as the isotactic D-PLA and L-PLA moieties, each of which carries potential for crystallization.

1.3 This specification is specifically not applicable to amorphous poly(lactide-co-glycolide) or poly(lactide)-based resins able to be fully solvated at 30°C by either methylene chloride (dichloromethane) or chloroform (trichloromethane), which are covered in Specification F2579 and typically possess molar glycolide levels of ~50 % or less. This specification is not applicable to lactide-based polymers or copolymers that possess isotactic polymeric segments sufficient in size to carry potential for lactide-based crystallization, which are covered by Specification F1925 and typically possess nominal mole fractions that equal or exceed 50 % L-lactide.

1.4 This specification addresses material characteristics of both virgin poly(glycolide) and poly(>70 % glycolide-co-lactide) resins intended for use in surgical implants and does not apply to packaged and sterilized finished implants fabricated from these materials.

1.5 As with any material, some characteristics may be altered by processing techniques (such as molding, extrusion, machining, assembly, sterilization, etc.) and so forth) required for the production of a specific part or device. Therefore, properties of fabricated forms of this resin should be evaluated independently using appropriate test methods to assure safety and efficacy.

1.6 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

1.7 *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.*

1.8 *This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.*

<sup>1</sup> This specification is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.11 on Polymeric Materials.

Current edition approved Dec. 15, 2018. Published January 2019. Originally approved in 2003. Last previous edition approved in 2010 as F2313 – 08 F2313 – 10. DOI: 10.1520/F2313-10.10.1520/F2313-18.

## 2. Referenced Documents

### 2.1 ASTM Standards:<sup>2</sup>

- [D1505](#) Test Method for Density of Plastics by the Density-Gradient Technique  
[D2857](#) Practice for Dilute Solution Viscosity of Polymers  
[D3418](#) Test Method for Transition Temperatures and Enthalpies of Fusion and Crystallization of Polymers by Differential Scanning Calorimetry  
[D5296](#) Test Method for Molecular Weight Averages and Molecular Weight Distribution of Polystyrene by High Performance Size-Exclusion Chromatography  
[D4603](#) Test Method for Determining Inherent Viscosity of Poly(Ethylene Terephthalate) (PET) by Glass Capillary Viscometer  
~~[E386](#) Practice for Data Presentation Relating to High-Resolution Nuclear Magnetic Resonance (NMR) Spectroscopy (Withdrawn 2015)<sup>3</sup>~~  
[E473](#) Terminology Relating to Thermal Analysis and Rheology  
[E793](#) Test Method for Enthalpies of Fusion and Crystallization by Differential Scanning Calorimetry  
[E794](#) Test Method for Melting And Crystallization Temperatures By Thermal Analysis  
[E967](#) Test Method for Temperature Calibration of Differential Scanning Calorimeters and Differential Thermal Analyzers  
[E968](#) Practice for Heat Flow Calibration of Differential Scanning Calorimeters  
[E1142](#) Terminology Relating to Thermophysical Properties  
[E1252](#) Practice for General Techniques for Obtaining Infrared Spectra for Qualitative Analysis  
[E1356](#) Test Method for Assignment of the Glass Transition Temperatures by Differential Scanning Calorimetry  
[E1994](#) Practice for Use of Process Oriented AOQL and LTPD Sampling Plans  
[E2977](#) Practice for Measuring and Reporting Performance of Fourier-Transform Nuclear Magnetic Resonance (FT-NMR) Spectrometers for Liquid Samples  
[F748](#) Practice for Selecting Generic Biological Test Methods for Materials and Devices  
[F1925](#) Specification for Semi-Crystalline Poly(lactide) Polymer and Copolymer Resins for Surgical Implants  
[F2579](#) Specification for Amorphous Poly(lactide) and Poly(lactide-co-glycolide) Resins for Surgical Implants  
[F2902](#) Guide for Assessment of Absorbable Polymeric Implants

### 2.2 ANSI Standards:<sup>3</sup>

- [ANSI/ISO/ASQ 13485](#) Medical devices -- Quality management systems -- Requirements for regulatory purposes  
[ANSI/ISO/ASQ Q9000](#) Quality Management Systems; Fundamentals and Vocabulary  
[ANSI/ISO/ASQ Q9001](#) Quality Management Systems; Requirements

### 2.3 ISO Standards:<sup>3</sup>

- ~~[ISO 31-8](#) Physical Chemistry and Molecular Physics—Part 8: Quantities and Units~~  
[ISO 10993](#) Biological Evaluation of Medical Devices  
[ISO 11357](#) Plastics—Differential Scanning Calorimetry (DSC)  
[ISO 80000-9](#) Quantities and units -- Part 9: Physical chemistry and molecular physics

### 2.4 U. S. Pharmacopeia (USP) Standard:<sup>4</sup>

- ~~[USP30/NF25](#)~~ [USP 232](#) United States Pharmacopeia (USP); Pharmacopeia: Elemental May 2, 2007 Impurities – Limits  
[USP 233](#) United States Pharmacopeia: Elemental Impurities – Procedure  
[USP 788](#) United States Pharmacopeia: Particulate Matter in Injections

### 2.5 Other Documents/Websites:

- ~~[ICH Q3C\(R3\)](#)~~ [ICH Q3C](#) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Quality Guideline: Impurities: Residual Solvents<sup>5</sup>  
[ICH Q3D](#) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: Guideline for Elemental Impurities<sup>5</sup>  
[21 CFR 820](#) Code of Federal Regulations, Title 21, Part 820, Quality System Regulation<sup>6</sup>  
[NIST Special Publication SP811](#) Guide for the Use of the International System of Units (SI)<sup>7</sup>  
[FDA Guidance](#) “Use of International Standard ISO 10993-1, ‘Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process’ – Guidance for Industry and Food and Drug Administration Staff

<sup>2</sup> For referenced ASTM standards, visit the ASTM website, [www.astm.org](http://www.astm.org), or contact ASTM Customer Service at [service@astm.org](mailto:service@astm.org). For *Annual Book of ASTM Standards* volume information, refer to the standard’s Document Summary page on the ASTM website.

<sup>3</sup> Available from American National Standards Institute (ANSI), 25 W. 43rd St., 4th Floor, New York, NY 10036, <http://www.ansi.org>.

<sup>4</sup> Available from U.S. Pharmacopeia (USP), 12601 Twinbrook Pkwy., Rockville, MD 20852-1790, <http://www.usp.org>.

<sup>5</sup> Available from ICH Secretariat, c/o IFPMA, 30 rue de St-Jean, P.O. Box 758, 1211 Geneva 13, Switzerland. Available online at <http://www.ich.org/LOB/media/MEDIA423.pdf>.

<sup>6</sup> Available from U.S. Government Printing Office Superintendent of Documents, 732 N. Capitol St., NW, Mail Stop: SDE, Washington, DC 20401, <http://www.access.gpo.gov>.

<sup>7</sup> Available from National Institute of Standards and Technology (NIST), 100 Bureau Dr., Stop 1070, Gaithersburg, MD 20899-1070, at <http://physics.nist.gov/cuu/Units/bibliography.html>.

### 3. Terminology

#### 3.1 Definitions:

3.1.1 *virgin polymer, n*—the initially delivered form of a polymer as synthesized from its monomers and prior to any processing or fabrication into a medical device.

### 4. Materials and Manufacture

4.1 All raw monomer components and other materials contacting either the raw monomer(s) or resin product shall be of a quality suitable to allow for use of such resin in the manufacture of an implantable medical product. Such quality includes adequate control of particles and other potential contaminants that may affect either the toxicity of or the cell response to the as-implanted or degrading final product.

4.2 All polymer manufacturing (including monomer handling, synthesis, pelletization/grinding and all subsequent steps) shall be undertaken under conditions suitable to allow for use of such resin in the manufacture of an implantable medical product.

### 5. Chemical Composition

5.1 The poly(glycolide) polymers covered by this specification shall be composed of glycolide or a combination of glycolide or lactide where the lactide content does not exceed 30 % mole fraction (34.7 % by mass fraction). To assure such composition and the attainment of the desired properties, the following tests are to be conducted.

#### 5.2 Chemical Identification:

5.2.1 The identity of the virgin polymer shall be confirmed either by infrared, <sup>1</sup>H-NMR, or <sup>13</sup>C-NMR spectroscopy.

#### 5.2.2 Infrared Identification:

5.2.2.1 Identity of either poly(glycolide) homopolymer or poly(glycolide-co-lactide) copolymer may be confirmed through an infrared spectrum exhibiting major absorption bands only at the wavelengths that appear in a suitable reference spectrum. Analysis shall be conducted using infra-red spectroscopy ~~practices~~methods similar to those described in Practice E1252. Typical infrared transmission and absorbance reference spectra are presented for PGA homopolymer in Fig. 1 and 90 % PGA:10 % L-PLA copolymer in Fig. 2. While poly(glycolide-co-lactide) copolymers will each have their own respective spectrum that will vary in response to copolymer ratio, this analytic method typically lacks sensitivity sufficient for quantification of copolymer ratio as specified in 7.1.2.

5.2.2.2 Additional or variable spectral bands may be indicative of sample crystallinity or either known or unknown impurities, including residual monomer, solvents, and ~~catalysts~~ (refer catalysts. Refer to limits specified in Table 1).

#### 5.2.3 Proton Nuclear Magnetic Resonance (<sup>1</sup>H-NMR) Identification:

5.2.3.1 Identity of either poly(glycolide) homopolymer or poly(glycolide-co-lactide) copolymer may be confirmed through sample dissolution, <sup>1</sup>H-NMR spectroscopy, and the use of a suitable reference spectrum. Sample dissolution is in either deuterated hexafluoroisopropanol (D-HFIP) or other substantially proton-free solvent able to fully solvate the specimen without inducing competing spectral bands. Analysis shall be conducted using ~~practices~~methods similar to those described in Practice E386E2977.

5.2.3.2 Additional spectral bands may be indicative of known or unknown impurities, including residual monomer, solvents, and catalysts (refer to limits specified in Table 1).

#### 5.2.4 Carbon-13 Nuclear Magnetic Resonance (<sup>13</sup>C-NMR) Identification:

5.2.4.1 Identity of either poly(glycolide) homopolymer or poly(glycolide-co-lactide) copolymer may be confirmed in a solid state through <sup>13</sup>C-NMR spectroscopy and the use of a suitable reference spectrum. Analysis shall be conducted using ~~practices~~methods similar to those described in Practice E386E2977.

5.2.4.2 Additional spectral bands may be indicative of known or unknown impurities, including residual solvents and ~~catalysts~~ (refer catalysts. Refer to the limits specified in Table 1).



#### 5.3 Molar Mass:

NOTE 1—The term molecular weight (abbreviated MW) is obsolete and should be replaced by the SI (Système Internationale) equivalent of either relative molecular mass ( $M_r$ ), which reflects the dimensionless ratio of the mass of a single molecule to an atomic mass unit [see ISO 31-8;880000-9], or molar mass ( $M$ ), which refers to the mass of a mole of a substance and is typically expressed as grams/mole. For polymers and other macromolecules, use of the symbols  $M_w$ ,  $M_n$ , and  $M_z$  continue, referring to mass-average molar mass, number-average molar mass, and z-average molar mass, respectively. For more information regarding proper utilization of SI units, see NIST Special Publication SP811.

5.3.1 The molar mass of the virgin polymer shall be indicated by inherent viscosity (IV) in dilute ~~solution~~ (IV). ~~solution~~. In addition to ~~inherent viscosity~~ (but not in place of), of inherent viscosity, mass average molar mass and molar mass distributions may be determined by gel permeation chromatography (GPC) according to the general procedure described in Test Method D5296, but using hexafluoroisopropanol (HFIP) solvent and poly methylmethacrylate (PMMA) calibration standards.



NOTE 2—Molar mass calibration standards (for example, polystyrene or polymethylmethacrylate) provide relative values only, and are not to be confused with an absolute determination of a lactide-based polymer's molar mass.

5.3.1.1 Determine the inherent viscosity of the polymer either in hexafluoroisopropanol (HFIP) or hexafluoroacetone sesquihydrate (HFAS) at 30°C using procedures similar to those described in Practice D2857 and Test Method D4603. Determination at a lower temperature of 25°C is allowable, provided the utilized equipment delivers the required thermal control



NOTE 1—Supplied example infra-red spectrum is of “Dexon Medical Suture (beige)” as acquired from the Hummel Polymer Library, available from: Thermo Nicolet Corporation, 5225 Verona Road, Madison, WI 53711-4495, USA.

**FIG. 1 Poly(glycolide) Resin Infrared Spectrum**



NOTE 1—Supplied example infra-red spectrum is of “Vicryl Medical Suture (violet)” as acquired from the Hummel Polymer Library, available from: Thermo Nicolet Corporation, 5225 Verona Road, Madison, WI 53711-4495, USA.

**FIG. 2 Poly(90 % glycolide-co-10 % lactide) Resin Infrared Spectrum**

**TABLE 1 Physical/Chemical Property Requirements for Virgin Poly(glycolide) and Poly(glycolide-co-lactide) Resins**

Analyte	Total Residual Monomer, (%)	Total Solvent Combination Residual(s) (in ppm)	Individual Solvent Residual(s) and Applicable ICH Limit(s) (in ppm)	(Optional) Residual Water (%)	Heavy Metals; (ppm as Pb)	(Optional) Residual Catalyst (in ppm)	Copolymer Ratio
Requirement	≤2.0% (by mass)	<1000 ppm	Report both for all solvent(s) utilized	≤0.5% (by mass) <sup>A</sup>	≤10 ppm (minus Sn)	≤100 ppm Sn	±3% of target (by mole)

**TABLE 1 Physical/Chemical Property Requirements for Virgin Poly(glycolide) and Poly(glycolide-co-lactide) Resins**

Analyte	Total Residual Monomer, (%)	Total Solvent Combination Residual(s) (in ppm)	Individual Solvent Residual(s) and Applicable ICH Limit(s) (in ppm)	(Optional) Residual Water (%)	Elemental Impurities (except catalyst)	Residual Catalyst (in ppm)	Copolymer Ratio
Requirement	≤2.0% (by mass)	<1000 ppm	Report both for all solvent(s) utilized	≤0.5% (by mass) <sup>A</sup>	Report compliance per USP <232> <sup>B</sup>	Report per USP <233> <sup>C</sup>	±3% of target (by mole)

<sup>A</sup> Utilizing a moisture determination method agreed upon by the supplier and the purchaser.

<sup>B</sup> See Section 5.6.3

<sup>C</sup> See Section 5.7.1 and Note 4.

and, if requested by the purchaser, an experimentally supported 30°C equivalent concentration-appropriate extrapolated result is also reported within the supplied certification. Note that any incomplete sample dissolution, precipitation from solution, or the formation of gels will produce inconsistency and variation in observed drop times.

NOTE 3—The IV test duration for each sample should be minimized to reduce risk of resin concentration changes due to evaporative loss of solvent.

5.3.1.2 Inherent viscosity is determined utilizing the following:

$$IV = \frac{\ln(t/t_o) v}{w} \quad (1)$$

or

$$IV = \frac{\ln(t/t_o)}{C} \quad (2)$$

where:

$IV$  = inherent viscosity (at 30°C in dL/g),

$t$  = efflux time in seconds for diluted solution,

$t_o$  = efflux time in seconds for source solvent,

$w$  = mass of polymer being diluted (in grams),

$v$  = dilution volume in deciliters (Note: 1 dL = 100 mL), and

$C$  = concentration of dilute solution ( $w/v$ ).

5.3.1.3 Resin concentration shall be 0.5 %  $w/v$  or less, with resin analyte concentrations of 0.1 %  $w/v$  (that is, 0.001 g/mL or 1 mg/mL) recommended. When reporting results, identify the solvent utilized, analyte concentration, and analysis temperature.

#### 5.4 Residual Monomer:

5.4.1 The virgin polymer shall have a combined total residual monomer content less than or equal to 2.0 % in mass fraction.

5.4.1.1 Determine the mass fraction of residual monomer by gas chromatography, HPLC, <sup>1</sup>H-NMR spectroscopy (using D-HFIP or other substantially proton-free solvent able to fully solvate the specimen), or other suitably sensitive analytic method as agreed upon by the supplier and purchaser.

#### 5.5 Residual Solvents:

5.5.1 If any solvent is utilized in any resin manufacturing or purification step, determine the residual levels of any utilized solvent(s) by gas chromatography or other suitable method as agreed upon by the supplier and purchaser. Acceptable residual levels of a particular solvent shall be reflective of toxicity, with a maximum acceptable limit consistent with ICH Q3C(R3)-Q3C. The detection limit for the chosen analytic method must shall be adequate to assure compliance with the applicable ICH guideline and the determined residual(s) and applied concentration limit(s) shall be reported. If no ICH concentration guideline has been established for a utilized solvent, an entry of “no ICH guidance available” shall be reported in lieu instead of a limit.

5.5.2 To minimize potential for toxic interaction of solvent combinations, cumulative Total Solvent Combination Residuals shall be limited to 1000 ppm (refer to the limit specified in Table 1). This limit carries the effect of allowing ICH QC3 Quality Guidelines when a single solvent system is utilized and less than 1000 ppm when combinations of more than one solvent are utilized (regardless of individual solvent toxicity).

#### 5.6 Heavy Metals:Elemental Impurities: